Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.63 |
| ▸ | CFD | P00746 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | PRKCG | P05129 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943747 | 0.93 | HDAC6 (0.79) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL5726547 | 0.91 | CFD (0.71) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL3029694 | 0.89 | HDAC8 (0.67) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL3025457 | 0.88 | HDAC6 (0.91) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL5944120 | 0.88 | HDAC1 (0.73) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL5943722 | 0.87 | HDAC8 (0.72) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL3031649 | 0.87 | HDAC8 (0.85) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL6386658 | 0.87 | HDAC6 (1.00) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL5943848 | 0.85 | HDAC8 (0.72) | HDAC6HDAC8HDAC2HDAC1HDAC3 | |
| SCHEMBL6183707 | 0.84 | ERN1 (0.61) | HDAC6HDAC8HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | HDAC6 11/4885HDAC8 9/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.